TY - JOUR
T1 - Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci
AU - Ellinghaus, David
AU - Jostins, Luke
AU - Spain, Sarah L.
AU - Cortes, Adrian
AU - Bethune, Jörn
AU - Han, Buhm
AU - Park, Yu Rang
AU - Raychaudhuri, Soumya
AU - Pouget, Jennie G.
AU - Hübenthal, Matthias
AU - Folseraas, Trine
AU - Wang, Yunpeng
AU - Esko, Tonu
AU - Metspalu, Andres
AU - Westra, Harm Jan
AU - Franke, Lude
AU - Pers, Tune H.
AU - Weersma, Rinse K.
AU - Collij, Valerie
AU - D'Amato, Mauro
AU - Halfvarson, Jonas
AU - Jensen, Anders Boeck
AU - Lieb, Wolfgang
AU - Degenhardt, Franziska
AU - Forstner, Andreas J.
AU - Hofmann, Andrea
AU - Schreiber, Stefan
AU - Mrowietz, Ulrich
AU - Juran, Brian D.
AU - Lazaridis, Konstantinos N.
AU - Brunak, SØren
AU - Dale, Anders M.
AU - Trembath, Richard C.
AU - Weidinger, Stephan
AU - Weichenthal, Michael
AU - Ellinghaus, Eva
AU - Elder, James T.
AU - Barker, Jonathan N.W.N.
AU - Andreassen, Ole A.
AU - McGovern, Dermot P.
AU - Karlsen, Tom H.
AU - Barrett, Jeffrey C.
AU - Parkes, Miles
AU - Brown, Matthew A.
AU - Franke, Andre
N1 - Funding Information:
We thank all patients with ankylosing spondylitis, Crohn's disease, PSC, psoriasis and ulcerative colitis, their families, healthy control individuals and clinicians for their participation in this study. We thank T. Wesse, T. Henke, S. Sedghpour Sabet, R. Vogler, G. Jacobs, I. Urbach, W. Albrecht, V. Pelkonen, K. Holm, H. Dahlen Sollid, B. Woldseth, J.A. Anmarkrud and L. Wenche TorbjØrnsen for expert help. F. Braun, W. Kreisel, T. Berg and R. Günther are acknowledged for contributing German patients with PSC. B.A. Lie and the Norwegian Bone Marrow Donor Registry at Oslo University Hospital, Rikshospitalet, in Oslo and the Nord-TrØndelag Health Study (HUNT) are acknowledged for sharing the healthy Norwegian controls. This work was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (SysInflame grant 01ZX1306A). This project received infrastructure support from Deutsche Forschungsgemeinschaft (DFG) Excellence Cluster 306 'Inflammation at Interfaces' and the PopGen Biobank. A.F. receives an endowment professorship by the Foundation for Experimental Medicine (Zurich, Switzerland). The Estonian Genome Center at the University of Tartu (EGCUT) received targeted financing from Estonian Research Council grant IUT20-60, the Center of Excellence in Genomics (EXCEGEN) and the University of Tartu (SP1GVARENG). We acknowledge EGCUT technical personnel, especially V. Soo and S. Smit. Data analyses were carried out in part at the High-Performance Computing Center of the University of Tartu. We acknowledge support from the UK Department of Health via National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre awards to Guy's and St Thomas' National Health Service (NHS) Foundation Trust in partnership with King's College London and to Addenbrooke's Hospital in partnership with the University of Cambridge. The study was supported by the German Federal Ministry of Education and Research (BMBF), within the context of National Genome Research Network 2 (NGFN-2), National Genome Research Network plus (NGFNplus) and the Integrated Genome Research Network (IG) MooDS (grants 01GS08144 and 01GS08147). R.K.W. is supported by a VIDI grant (016.136.308) from the Netherlands Organization for Scientific Research (NWO). J.H. was supported by the Swedish Research Council (521-2011-2764). This work is supported in part by funding from the US NIH (1R01AR063759 (S.R.), 5U01GM092691-05 (S.R.), 1UH2AR067677-01 (S.R.), U19AI111224-01 (S.R.) and 1R01DK084960-05 (K.N.L.)) and Doris Duke Charitable Foundation grant 2013097. A.B.J. and S.B. acknowledge funding from the Novo Nordisk Foundation (grant NNF14CC0001) and the H2020 project MedBioinformatics (grant 634143). The study was supported by the Norwegian PSC Research Center. We thank G. Trynka for assistance in setting up GoShifter.
Publisher Copyright:
© 2016 Nature America, Inc.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - We simultaneously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to investigate pleiotropy and the relationship between these clinically related diseases. Using high-density genotype data from more than 86,000 individuals of European ancestry, we identified 244 independent multidisease signals, including 27 new genome-wide significant susceptibility loci and 3 unreported shared risk loci. Complex pleiotropy was supported when contrasting multidisease signals with expression data sets from human, rat and mouse together with epigenetic and expressed enhancer profiles. The comorbidities among the five immune diseases were best explained by biological pleiotropy rather than heterogeneity (a subgroup of cases genetically identical to those with another disease, possibly owing to diagnostic misclassification, molecular subtypes or excessive comorbidity). In particular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel disease is likely the result of a unique disease, which is genetically distinct from classical inflammatory bowel disease phenotypes.
AB - We simultaneously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to investigate pleiotropy and the relationship between these clinically related diseases. Using high-density genotype data from more than 86,000 individuals of European ancestry, we identified 244 independent multidisease signals, including 27 new genome-wide significant susceptibility loci and 3 unreported shared risk loci. Complex pleiotropy was supported when contrasting multidisease signals with expression data sets from human, rat and mouse together with epigenetic and expressed enhancer profiles. The comorbidities among the five immune diseases were best explained by biological pleiotropy rather than heterogeneity (a subgroup of cases genetically identical to those with another disease, possibly owing to diagnostic misclassification, molecular subtypes or excessive comorbidity). In particular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel disease is likely the result of a unique disease, which is genetically distinct from classical inflammatory bowel disease phenotypes.
UR - http://www.scopus.com/inward/record.url?scp=84964772502&partnerID=8YFLogxK
U2 - 10.1038/ng.3528
DO - 10.1038/ng.3528
M3 - Article
C2 - 26974007
AN - SCOPUS:84964772502
SN - 1061-4036
VL - 48
SP - 510
EP - 518
JO - Nature Genetics
JF - Nature Genetics
IS - 5
ER -